Tangen wins contract for Candida auris point-of-care test

By LabPulse.com staff writers

June 29, 2020 -- Tangen Biosciences has won a contract with the New York State Department of Health's Wadsworth Center, a large public health laboratory, to develop a rapid skin swab test for the treatment-resistant fungus Candida auris.

The C. auris test will run on the company's TangenDx platform, which includes an assay kit and the company's GeneSpark analyzer. Tangen currently markets rapid tests for bloodstream Candida infections, bacterial infections, and antimicrobial resistance. It plans to file an emergency use authorization for a point-of-care COVID-19 test with the U.S. Food and Drug Administration this summer.

Tangen advances anthrax test with BARDA funding
Branford, CT-based Tangen Biosciences is advancing development of an anthrax test through funding from the U.S. Biomedical Advanced Research and Development...
FDA clears 2 Hologic tests for yeast infections
The U.S. Food and Drug Administration (FDA) has cleared two diagnostic tests from Hologic for diagnosing vaginitis, or yeast infections, the company announced...
Labs gear up to diagnose novel fungal infection
Clinical laboratories are being advised by the U.S. Centers for Disease Control and Prevention on how to handle a relatively new fungal infection, Candida...

Copyright © 2020 LabPulse.com

Last Updated ls 7/2/2020 11:29:56 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.